We develop phase-appropriate formulations for liquid, frozen and lyophilized drug products, focusing on your target product profile (TPP) and designing the study to meet your requirements. We consider drug substance availability, relevant deadlines and your overall development strategy when conducting a project. Additionally, our comprehensive capabilities offer the flexibility to readily switch from a liquid to a lyophilized formulation or explore formulation types in parallel.

Determining the identity and possible origin of particulate matter in biopharmaceutical drug products is crucial for troubleshooting and root-cause analysis, and therefore, it is often very time sensitive. Coriolis experts can analyze your samples within a matter of days so you can quickly resolve the underlying cause of particle formation.

Coriolis Pharma offers ICH-compliant stability studies (long-term, accelerated, in-use) and GMP release testing for biopharmaceuticals. Services include method development, validation, and lot release testing for complex biologics and viral vectors.

Coriolis Pharma offers comprehensive lyophilization process development, including cycle design, optimization, scale-up, and transfer, tailored for biopharmaceutical drug products.

Coriolis Pharma’s in silico developability assessment helps to identify lead candidates with the highest success potential while defining formulation-relevant parameters. This method enables early detection of critical risks, including colloidal and conformational instability, aggregation, high viscosity, and chemical degradation pathways such as oxidation and deamidation—all without the need for physical material.